Clinical trials: Cholangiocarcinoma Cancer
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have…
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma
- Trial name
- NCT03368963
- Testing
- Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Emory University
Cholangiocarcinoma, Chemotherapy Effect
Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin
A Phase 2 clinical trial protocol for evaluating the efficacy and safety of OBI-833/OBI-821, a carbohydrate-conjugate vaccine combined with an immune adjuvant, as maintenance therapy in combination with first-line gemcitabine and…
- Conditions
- Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
- Trial name
- NCT06490198
- Testing
- OBI-833/OBI-821
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Chang Gung Memorial Hospital
Advanced Solid Tumors, Hematologic Neoplasms
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with…
- Conditions
- Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors
- Trial name
- NCT03219268
- Testing
- tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg
- Where
- 40 sites in United States, Australia and 6 more
- Volunteers
- 277 people
- Sponsor
- MacroGenics
Hepatocellular Carcinoma, Cholangiocarcinoma
Hepatobiliary Tumors Tissue Samples Acquisition
Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, so it is of great significance to find important prognostic markers and then screen out specific subgroups of people; meanwhile, chronic hepatitis…
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Gallbladder Cancer, Biliary Tract Cancer
- Trial name
- NCT04445532
- Testing
- Gene expression analysis, Genomic analysis, Protein expression analysis
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Colon Cancer, Gastric Cancer
A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies
A randomized control trial to evaluate the feasibility of implementing a patient educational platform (PEP) for patients with gastrointestinal malignancies undergoing active chemotherapy treatment.
- Conditions
- Colon Cancer, Gastric Cancer, Pancreas Cancer, Rectal Cancer
- Trial name
- NCT04316078
- Testing
- patient engagement platform
- Where
- Israel
- Volunteers
- 126 people
- Sponsor
- Sheba Medical Center
Intrahepatic Cholangiocarcinoma
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with anti-pd-1 antibody in patients with advanced hepatocellular carcinoma after progression on first line systemic therapy.
- Trial name
- NCT04299581
- Testing
- Camrelizumab, US/CT-guided Percutaneous Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Extrahepatic Bile Duct Cancer, Pancreatic Cancer
Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00010088
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- 50 sites in France, Luxembourg
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
This phase I trial studies the side effects and best dose of gemcitabine and cisplatin when given together with ivosidenib or pemigatinib in treating patients with cholangiocarcinoma that cannot be removed with surgery…
- Conditions
- Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Unresectable Cholangiocarcinoma
- Trial name
- NCT04088188
- Testing
- Cisplatin, Gemcitabine, Ivosidenib
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Academic and Community Cancer Research United
Cholangiocarcinoma, Pancreas Cancer
RFA for Malignant Biliary Obstruction
Pancreatic cancer and cholangiocarcinoma are the most common causes of malignant biliary obstruction. They are diseases of increasing incidence and unfavorable prognosis.
- Trial name
- NCT03166436
- Testing
- Radiofrequency ablation, Biliary stenting
- Where
- Czechia
- Volunteers
- 140 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Bile Duct Cancer
Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
The goal of this clinical trial is to provide evidence for the general tolerability of radiofrequency ablation (bRFA) in patients with unresectable bile duct cancer undergoing systemic palliative treatment consisting of systemic…
- Trial name
- Ablatio (NCT06274879)
- Testing
- Gemcitabin, Cisplatin and Durvalumab, Biliary Radiofrequency Ablation, Endoscopic Retrograde Cholangio-Pancreatography with stenting
- Where
- 4 sites in Switzerland
- Volunteers
- 36 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
BTC-Ag-T (ACH-AgT001) is an autologous experimental T-cell therapy designed for advanced biliary tract cancer. This is an open-label, single-arm Phase 1 study to evaluate the safety, tolerability, and preliminary efficacy of…
- Conditions
- Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Perihilar
- Trial name
- NCT07614061
- Testing
- BTC-Ag-T (ACH-AgT001), Cyclophosphamide and Fludarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Neoplasms, Neuroendocrine Tumors
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
This is a prospective pilot study designed to document safety and efficacy of liver-directed therapy for colorectal, neuroendocrine, cholangiocarcinoma, melanoma, and breast cancer metastases to the liver using Yttrium-90 glass…
- Conditions
- Colorectal Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Melanoma
- Trial name
- NCT01290536
- Testing
- Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)
- Volunteers
- 42 people
- Sponsor
- Nicholas Fidelman, MD
Colorectal Cancer, Gastro Esophageal Junctional Cancer
IKS04 Regimen in Advanced Solid Tumors That Express CA242
This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further…
- Conditions
- Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
- Trial name
- NCT07738939
- Testing
- IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Iksuda Therapeutics Ltd.
Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
This phase I trial studies the side effects of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel in combination with gemcitabine and cisplatin in treating patients with biliary tract cancer that has…
- Conditions
- Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
- Trial name
- NCT05285358
- Testing
- Cisplatin, Gemcitabine, Nab-paclitaxel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Patients With Biliary Stricture Treated During ERCP With Available MRCP and Abdominal CT Scan
Preclinical Development of a 3D Bili-MRI Reconstruction Tool and an Artificial Intelligence Algorithm to Assist Endoscopists in Performing Endoscopic Retrograde Cholangiopancreatography (ERCP)
ERCP is a complex interventional endoscopic procedure based on 2D visualization of the biliary tract. 3D modeling and AI are promising solutions to improve navigation and safety during ERCP.
- Trial name
- MAAGIE (NCT07401485)
- Testing
- retrospective study based on data already collected during routine care (no intervention)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well lapatinib ditosylate works in treating patients with unresectable liver or…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00107536
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma, Pancreatic Cancer
Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry
The objective of this protocol is to establish a multicenter registry to evaluate the impact of radiofrequency ablation in the management of patients with pancreatico-biliary disorders including malignancies.
- Conditions
- Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Cancer, Biliary Stricture
- Trial name
- RFA-Registry (NCT01439698)
- Testing
- Radio Frequency ablation Probe
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
This phase III trial studies how well gemcitabine hydrochloride and cisplatin given with or without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body.
- Conditions
- Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8
- Trial name
- NCT03768414
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel
- Where
- 692 sites in United States
- Volunteers
- 452 people
- Sponsor
- SWOG Cancer Research Network
Depression
Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)
Anxiety and depression have been found to be significant co-occurring conditions in cancer patients. This study examines these and other psychological conditions in patients diagnosed with cholangiocarcinoma, a rare cancer of the…
- Trial name
- NCT00737399
- Testing
- Lifestyle Counseling with Emotional Freedom Techniques (EFT)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Soul Medicine Institute
Pancreatic Cancer, Gastric Cancer
Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers
This study is for people with advanced cancer of the digestive tract and cancer that cannot be completely removed by surgery. Radiation therapy is commonly used in the treatment of these types of cancer in combination with a…
- Conditions
- Pancreatic Cancer, Gastric Cancer, Duodenum Cancer, Bile Duct Cancer
- Trial name
- NCT00183846
- Testing
- irinotecan, radiation therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.